<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="38561,38562">Fluvastatin</z:chebi> has been shown to revert proinflammatory/prothrombotic effects of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) in vitro and in mice </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we examined whether <z:chebi fb="0" ids="38561,38562">fluvastatin</z:chebi> affects the levels of proinflammatory/prothrombotic markers in <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) patients </plain></SENT>
<SENT sid="2" pm="."><plain>Vascular endothelial growth factor (VEGF), soluble tissue factor (sTF), <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-alpha), soluble intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (sICAM-1), sE-selectin (E-sel), C-reactive protein (CRP), and soluble vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule (sVCAM-1), were measured in the sera of 93 APS patients and 60 controls and in the sera of nine patients with APS before and after 30 days of treatment with <z:chebi fb="0" ids="38561,38562">fluvastatin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Elevated levels of VEGF, sTF, and TNF-alpha were found in APS patients </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="38561,38562">Fluvastatin</z:chebi> significantly reduced those markers in the majority of treated subjects </plain></SENT>
<SENT sid="5" pm="."><plain>The data from this study show that <z:chebi fb="0" ids="35664">statins</z:chebi> may be beneficial in aPL-positive patients and warrant larger clinical trials to confirm the efficacy of the drug for the treatment of APS clinical manifestations </plain></SENT>
</text></document>